Sahar Yassine, MSc, LTSI - INSERM U1099, University of Rennes, NeuroKyma, and, Behavior and Basal Ganglia, CIC1414, CIC-IT, CHU Rennes, Rennes, France

Ute Gschwandtner, MD, Department of Neurology, Hospitals of the University of Basel, Basel, Switzerland

Manon Auffret, PharmD, PhD, INSERM U1099, University of Rennes, , Behavior and Basal Ganglia, CIC1414, CIC-IT, CHU Rennes, Institut des Neurosciences Cliniques de Rennes (INCR), Rennes, France, and  France Développement Electronique, Monswiller, France

Joan Duprez, PhD, LTSI - INSERM U1099, University of Rennes, Rennes, France

Marc Verin, MD, PhD, LTSI - INSERM U1099, University of Rennes, Behavior and Basal Ganglia, CIC1414, CIC-IT, CHU Rennes, Institut des Neurosciences Cliniques de Rennes (INCR),  and Movement Disorders Unit, Neurology Department, Pontchaillou University Hospital, Rennes, France

Peter Fuhr, MD, Department of Neurology, Hospitals of the University of Basel, Basel, Switzerland

Mahmoud Hassan, PhD, Behavior and Basal Ganglia, CIC1414, CIC-IT, CHU Rennes, and MINDIG, Rennes, France, and, School of Science and Engineering, Reykjavik University, Reykjavik, Iceland

Journal CME highlights various articles covering relevant issues, developments and research topics in the area of movement disorders. Articles are selected from Movement Disorders, the official Journal of the International Parkinson and Movement Disorder Society.

Upon completion of this activity learners will be able to:

1. Understand the three phenotype subgroups into which the patients in this study can be grouped
2. Evaluate how the identification of novel PD subtypes may provide a more accurate prognosis in individual patients in clinical practice and help to stratify subgroups in clinical trials
3. Assess the type of electroencephalography (EEG) that was obtained for this study

This activity is intended for clinicians, other health professionals, researchers, policy makers from throughout the world, both MDS members and non-members, who interact with patients living with Movement Disorders.

METHOD OF PARTICIPATION

Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

EVALUATION & CLAIMING CREDIT

Participants of this educational program will have the opportunity to claim their CME credits upon completion of the evaluation at the conclusion of the module. Please take time to complete the online evaluations as your input and comments are essential in planning future educational programs. The CME certificate is available immediately following the completion of the module.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available below. All relevant financial relationships have been mitigated in advance of this program.

Sara Schaefer: Course Director

Nothing to Disclose

Veronica Santini: Reviewer

Grant: Insightec, Biogen, Roche / Genentech

Sahar Yassine: Author

Nothing to Disclose

Ute Gschwandtner: Author

Nothing to Disclose

Manon Auffret: Author

Nothing to Disclose

Joan Duprez: Author

Nothing to Disclose

Marc Verin: Author

Nothing to Disclose

Peter Fuhr: Author

Nothing to Disclose

Mahmoud Hassan: Author

Nothing to Disclose

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

SATISFACTORY COMPLETION

Each module will take approximately one (1) hour to complete. Upon reading the article, participants will take a post-test and must receive a grade of 75% or higher to pass. Participants are allowed multiple attempts to complete the post-test. Once the post-test is passed, participants are required to complete the module evaluation.

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.

2. Compatible with Windows PC and MAC (256 MB of RAM or higher)

3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher

4. Adobe Flash Player 12.0 (or higher).

5. Adobe Reader to print certificate.

CONTENT VALIDITY STATEMENT

All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.